The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Open accessAbstract
Blockade of angiogenesis can retard tumour growth, but may also paradoxically increase metastasis. This paradox may be resolved by vessel normalization, which involves increased pericyte coverage, improved tumour vessel perfusion, reduced vascular permeability, and consequently mitigated hypoxia. Although these processes alter tumour progression, their regulation is poorly understood. Here we show that type 1 T helper (T H 1) cells play a crucial role in vessel normalization. Bioinformatic analyses revealed that gene expression features related to vessel normalization correlate with immunostimulatory pathways, especially T lymphocyte infiltration or activity. To delineate the causal relationship, we used various mouse models with vessel normalization or T lymphocyte deficiencies. Although disruption of vessel normalization reduced T lymphocyte infiltration as expected, reciprocal depletion or inactivation of CD4+ T lymphocytes decreased vessel normalization, indicating a mutually regulatory loop. In addition, activation of CD4+ T lymphocytes by immune checkpoint blockade increased vessel normalization. T H 1 cells that secrete interferon-γ are a major population of cells associated with vessel normalization. Patient-derived xenograft tumours growing in immunodeficient mice exhibited enhanced hypoxia compared to the original tumours in immunocompetent humans, and hypoxia was reduced by adoptive T H 1 transfer. Our findings elucidate an unexpected role of T H 1 cells in vasculature and immune reprogramming. T H 1 cells may be a marker and a determinant of both immune checkpoint blockade and anti-angiogenesis efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously demonstrated that vascular normalization could increase immune cells’ infiltration into tumors, and multiple studies have confirmed these findings in several tumor models (15,17-19).”
In the citing paper
“An improved vascular network favors adaptive antitumor immunity by promoting trafficking and re-localization of tumor-infiltrating lymphocytes (TILs), leading to improved outcomes of various immunotherapies, including immune checkpoint blockade (ICB) (15-20).”
In the citing paper
“There is an association of IFNγ-secreting T cells and vessel normalization (18), and IFNγ promotes the enhanced expression of adhesion molecules in endothelial cells (65).”
In the citing paper
“Lack of perfusion, tumoral hypoxia, and T-cell exclusion are considered significant resistance mechanisms (15,17-19).”
In the citing paper
“ICB of cytotoxic T lymphocyte protein 4 (CTLA-4) and PD-1 can normalize blood vessels in multiple models of transplanted breast and other tumours105.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [105]
In the citing paper
“ICB can have vessel-normalizing effects in preclinical models of breast tumours105, although the kinetics of vascular normalization are unknown.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [105]
In the citing paper
“The vascular normalization effect observed in this study was attributed to increased CD4+ type 1 T helper (TH1) cell accumulation and anticancer activity105.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [105]
In the citing paper
“This observation contrasts with the vascular normalization induced by ICB in breast cancer models105 and suggests that the vascular effects are dependent on the tumour location and/or type — a possibility that needs to be further investigated.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [105]
In the citing paper
“although the generalizability of the reciprocal regulation of tumour vessel normalization and immunostimulatory reprogramming is supported by analyses of large transcriptomic databases in human tumours, the experimental studies were limited to breast cancer models105.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
REVIGO summarizes and visualizes long lists of gene ontology terms
Supek, F., Bošnjak, M., Škunca, N., & Šmuc, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021800 · Cited by 6,264
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases
Xie, C., Mao, X., Huang, J., Ding, Y., Wu, J., Dong, S., Kong, L., Gao, G., Li, C., & Wei, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr483 · Cited by 5,078
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 849
Okuyama, K., Naruse, T., Matsushita, Y., Fujimoto, J., Yanamoto, S., Lei, Y. L., & Hu, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02609-6 · Cited by 9
Yao, Q., Gu, L., Su, R., Chen, B., & Cao, H. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15991 · Cited by 9
Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer
Li, G., Hu, J., Cho, C., Cui, J., Li, A., Ren, P., Zhou, J., Wei, W., Zhang, T., Liu, X., et al. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110729 · Cited by 10
Sun, C., Wang, Q., Hou, L., Zhang, R., Chen, Y., & Niu, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1229560 · Cited by 9
McCormick, A. L., Anderson, T. S., Daugherity, E. A., Okpalanwaka, I. F., Smith, S. L., Appiah, D., & Lowe, D. B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1241949 · Cited by 9
Qu, J., Li, L., Fu, G., Zheng, M., Geng, J., Sun, X., & Xing, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122422 · Cited by 10
Transmural Flow Upregulates PD‐L1 Expression in Microvascular Networks
Wan, Z., Zhang, S., Zhong, A. X., Xu, L., Coughlin, M. F., Pavlou, G., Shelton, S. E., Nguyen, H. T., Hirose, S., Kim, S., et al. (2024) · Advanced Science · doi:10.1002/advs.202400921 · Cited by 8
Human primed ILCPs support endothelial activation through NF-κB signaling
Vanoni, G., Ercolano, G., Candiani, S., Rutigliani, M., Lanata, M., Derré, L., Marcenaro, E., Schneider, P., Romero, P. J., Jandus, C., et al. (2021) · eLife · doi:10.7554/elife.58838 · Cited by 9
Liu, F., Yang, Z., Zheng, L., Shao, W., Cui, X., Wang, Y., Jia, J., & Fu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.690129 · Cited by 9
Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance
Kong, F., Wang, Z., Liao, D., Zuo, J., Xie, H., Li, X., & Jia, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739191 · Cited by 9
Tang, W., Yao, W., Jin, Z., Kong, Q., Hu, W.-K., Liang, Y., Chen, L.-X., Chen, S.-Y., Zhang, Q., Wei, X., et al. (2022) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28215 · Cited by 9
Role of angiopoietins in mesothelioma progression
Magkouta, S., Kollintza, A., Moschos, C., Spella, M., Skianis, I., Pappas, A., Vazakidou, M., Stathopoulos, G. T., & Kalomenidis, I. (2018) · Cytokine · doi:10.1016/j.cyto.2018.08.006 · Cited by 9
Interferon‐γ facilitated adjuvant‐induced arthritis at early stage
Ma, H., Xu, M., Song, Y., Zhang, T., Yin, H., & Yin, S. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12757 · Cited by 9
Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making
Stebbing, J., & Wasan, H. S. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01185 · Cited by 9
Marsh‐Wakefield, F., Santhakumar, C., Ferguson, A. L., Ashhurst, T. M., Shin, J., Guan, F. H. X., Shields, N. J., Platt, B. J., Putri, G., Gupta, R., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000540 · Cited by 8
Tumor-associated high endothelial venules as therapeutic modulation targets in cancer immunotherapy
Zhang, J.-Y., Piao, Z.-Y., Su, G.-L., Zhang, M.-J., & Sun, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189500 · Cited by 8
Ci, H., Wang, X., Shen, K., Du, W., Zhou, J., Fu, Y., Dong, Q., & Jia, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043324 · Cited by 8
Current status of neoadjuvant immunotherapy for the treatment of gastric cancer
Zhang, X., Лю, Б., Wang, R., Li, X., & Zhou, W. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03437-0 · Cited by 8
Self-citationChen, Y., Di, M., Tang, Y., Zhao, J., Wang, Q., Guo, Z., Li, Y., Ouyang, D., Yang, J., Chen, H., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03061-w · Cited by 9
Edelmann, M., Fan, S., Oliveira, T. D., Goldhardt, T., Sartorius, D., Midelashvili, T., Conrads, K., Paul, N. B., Beißbarth, T., Fleischer, J. R., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0077 · Cited by 8
Recent advancement in the spatial immuno-oncology
To, A., Zou, Y., & Sugimura, R. (2024) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2024.12.003 · Cited by 8
Yang, J., Song, K., Guo, W., Zheng, H., Fu, Y., You, T., Wang, K., Qi, L., Zhao, W., & Guo, Z. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0864 · Cited by 8
Fu, L., Chen, P., Wang, S., Liu, W., Chen, Z., Chen, H., & Fu, Z. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001163 · Cited by 8
It’s T Time for Normal Blood Vessels
Thienpont, B., & Lambrechts, D. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.04.005 · Cited by 9
Feng, C., Xu, Y., Liu, Y., Zhu, L., Wang, L., Cui, X., Lu, J., Zhang, Y., Zhou, L., Chen, M., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.619027 · Cited by 8
McAndrews, K. M., Mahadevan, K. K., & Kalluri, R. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041411 · Cited by 8
He, B., Dymond, L., Wood, K. H., Bastow, E. R., Satiaputra, J., Li, J., Johansson, A., Hamzah, J., Kumarasinghe, P. M., Ballal, M., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2406576 · Cited by 7
Martello, S. E., Xia, J., Kusunose, J., Hacker, B. C., Mayeaux, M. A., Lin, E. J., Hawkes, A., Singh, A., Caskey, C. F., & Rafat, M. (2024) · Theranostics · doi:10.7150/thno.97759 · Cited by 7
Research progress of immune checkpoint inhibitors in ovarian cancer
Zhao, L., Zhai, Y., & Niu, G. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00177 · Cited by 7
Natural medicines target tumor vascular microenvironment to inhibit tumor
Lu, Y., Guo, Z., Li, H., Wen, J., Zhang, X., Guan, X., Cui, X., & Cheng, M. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101623 · Cited by 7
Self-citationTherapeutic application of nanosystems-based metalloptosis for enhanced tumor radiotherapy
Chen, M., Chen, L., Mao, K., Shi, Y.-B., Sun, M., Zhou, Y., Li, Z., & Luo, G. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216666 · Cited by 8
Fu, Y., Duan, B., Zheng, P., Chu, H., Li, W., Yang, Y., Yang, Z., He, J., Wang, M., Li, S., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123524 · Cited by 7
Angeli, S., Neophytou, C., Charalambous, A., Voutouri, C., Themistokleous, P., Stylianopoulos, T., & Mpekris, F. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114546 · Cited by 7
Prognostic Biomarkers Identification in Esophageal Cancer Based on WGCNA and Single-Cell Analysis
Zhao, W.-J., Liu, Y., Guo, J., & Liu, H. (2022) · Disease Markers · doi:10.1155/2022/6595778 · Cited by 7
Zhong, J., Xiao, C., Chen, Q., Pan, X., Xu, T., Wang, Y., Hou, W., Liu, L., Cao, F., Wang, Y., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107734 · Cited by 7
Cheng, S., Li, B., Yu, J., & Wang, L. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.05.06 · Cited by 7
Gupta, M., Choi, H., Kemp, S. B., Furth, E. E., Pickup, S., Clendenin, C., Orlen, M., Rosen, M., Liu, F., Cao, Q., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-4049 · Cited by 7
High endothelial venules associated with better prognosis in esophageal squamous cell carcinoma
Li, H., Tang, L., Han, X., Zhong, L., Gao, W., Chen, Y., Huang, J., & Wen, Z. (2022) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2022.152051 · Cited by 7
Moshe, D. L., Baghaie, L., Leroy, F., Skapinker, E., & Szewczuk, M. R. (2023) · Biomedicines · doi:10.3390/biomedicines11082142 · Cited by 7
Wu, K., Li, Y., Li, Z., Zhou, Z., Ge, X., Li, Y., Han, X., Chen, P., & Ren, K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1143578 · Cited by 7
Luo, M.-C., Wu, J., Wu, J., Lin, Z.-T., Li, Y., Zeng, Z.-X., Wei, S.-M., & Yan, M.-L. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s425674 · Cited by 7
Shen, R., Jiang, Q., Li, P., Wang, D., Yu, C., Meng, T., Hu, F., & Yuan, H. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123512 · Cited by 7
Translating Preclinical Research for Exercise Oncology: Take It to the VO2max
Lamkin, D. M., & Garland, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.575657 · Cited by 8
Liu, H., Yang, T., & Choi, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1580559 · Cited by 7
Rovers, S., Audenaerde, J. R. M. V., Verloy, R., Waele, J. D., Brants, L., Hermans, C., Lau, H. W., Merlin, C., Ribas, M. M., Ponsaerts, P., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2512104 · Cited by 6
Vuong, L. H., Cornish, A. E., Pfeil, J. Q., Khandwala, Y. S., Jiang, H., Zheng, D. X. T., Mascareno, E. A., Rittenhouse, N., Rappold, P. M., Leibold, J., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.05.007 · Cited by 7
The covert symphony: cellular and molecular accomplices in breast cancer metastasis
Si, H., Esquivel, M., Mendoza, E. M., & Roarty, K. P. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1221784 · Cited by 6
Zhang, C., Chu, T., Wang, Q., Cheng, Y., Zhang, Y., Wang, R., Ma, L., Qian, C., Han, B., & Li, K. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0423 · Cited by 6
Biologically based strategies for overcoming in vivo barriers with functional nano‐delivery systems
Ahmadzadeh, R., Taheri, S. A., Mohammadi, N., Hjazi, A. M., Menon, S. V., Kadhum, W. R., Kumar, A., Shakir, M. N., Shayan, F. K., & Shirinkami, N. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23782 · Cited by 6
Liu, Z., Ma, K., Jia, Q., Yang, Y., Fan, P., Wang, Y., Wang, J., Sun, J., Sun, L., Shi, H., et al. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2024-000473 · Cited by 6
Mortazavi, S. M. A., & Firoozabadi, B. (2024) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-024-01891-x · Cited by 6
Kang, Y. Y., Kang, Y., Zhang, D., & Yao, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1460533 · Cited by 6
Prognostic value of eight immune gene signatures in pancreatic cancer patients
Wang, W., Xu, Z., Wang, N., Yao, R., Qin, T., Lin, H., & Yue, L. (2021) · BMC Medical Genomics · doi:10.1186/s12920-020-00868-w · Cited by 6
Zhuang, Z., Zhou, J., Qiu, M., Li, J., Lin, Z., Yi, H., Liu, X., Huang, C., Tang, B., Liu, B., et al. (2024) · Cancers · doi:10.3390/cancers16040832 · Cited by 6
Eso, Y., & Seno, H. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.04.004 · Cited by 6
LPPR5 Expression in Glioma Affects Growth, Vascular Architecture, and Sunitinib Resistance
Stange, L., Lucia, K. E., Ghori, A., Vajkoczy, P., Czabanka, M., & Broggini, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063108 · Cited by 6
LRG1 destabilizes tumor vessels and restricts immunotherapeutic potencyPreprint
O’Connor, M. N., Kallenberg, D. M., Jackstadt, R., Watson, H. A., Alatsatianos, M., Ohme, J., Camilli, C., Pilotti, C., Dritsoula, A., Bowers, C. E., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.12.334359 · Cited by 6
Chen, X., Li, W., Lei, X., Lei, X., Guo, Q., Ma, X., Luo, Y., Li, C., Wang, C., Guo, Q., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1429095 · Cited by 5
Han, Z., Yuanzeng, Z., Wu, G., & Peichun, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1587069 · Cited by 5
Xu, M., Pu, Y., Jiang, Y., Liu, Y., Feng, Y., Zhao, X., & Li, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-06625-2 · Cited by 5
Ning, Y., Lei, K. J., Gao, X., Kong, Y., Shan, Y., Tian, T., Cui, Z., & Ren, H. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70582 · Cited by 6
ZHU, Y., Wang, M., Cao, J., Song, H., & Zhang, P. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07354-w · Cited by 8
Wang, L., Feng, J.-K., Zhou, B., Liu, Z., Gong, L., Yan, M.-L., Zhao, H., Jiang, Y.-B., Shi, J., Guo, W.-X., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag054 · Cited by 6
Jia, G., Zhou, S., Xu, T., Huang, Y., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.954685 · Cited by 5
Deciphering CD4+ T cell‐mediated responses against cancer
Kirkpatrick, C. A., & Lu, Y. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23730 · Cited by 6
Guan, R., Li, C., Gu, F., Li, W., Wei, D., Cao, S., Chang, F., & Lei, D. (2024) · BMC Genomics · doi:10.1186/s12864-024-10321-2 · Cited by 5
Engineered CD4 T cells for in vivo delivery of therapeutic proteins
Radhakrishnan, H., Newmyer, S. L., Javitz, H. S., & Bhatnagar, P. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318687121 · Cited by 6
Li, Y., Zhang, M., Hu, Y., Du, B., Mo, Y., He, T., Zhao, M., Li, B., Xia, J., Huang, Z., et al. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251351109 · Cited by 6
KCTD10 inhibits lung cancer metastasis and angiogenesis via ubiquitin-mediated β-catenin degradation
Yin, Z., Long, S., Zhou, H., Ouyang, M., Wang, Q., He, J., Su, R., Li, Z., Ding, X., & Xiang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630311 · Cited by 5
Jiang, L., Li, M., & Zhao, Z. (2025) · Journal of Applied Microbiology · doi:10.1093/jambio/lxaf230 · Cited by 5
Evolution of tumor microenvironment in colorectal liver metastases under treatment stress
Huang, N., Zeng, D., Rong, X., Wang, C., Wu, Z., Guo, J., Wang, Y., Li, J., Li, J., Wang, J., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12259 · Cited by 5
Benefits and Pitfalls of Tumor Vessel Normalization
Park, J., Park, I., & Koh, G. Y. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_46 · Cited by 7
Tian, Y., Hu, Q., Zhang, R., Zhou, B., Xie, D., Wang, Y., & Yang, L. (2023) · MedComm – Oncology · doi:10.1002/mog2.21 · Cited by 5
Zhang, Y., Gao, J., He, Y., Qi, Z., Qian, L., Chen, W., Xu, H., Yue, Y., Mao, X., Guo, S., et al. (2023) · Journal of Immunology Research · doi:10.1155/2023/5867047 · Cited by 5
Self-citationWang, H., Hu, L., Zhang, F., Fang, M., Xu, J., Li, M., & Chen, Z. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.106814 · Cited by 5
Self-citationMorihara, H., Yamada, T., Tona, Y., Akasaka, M., Okuyama, H., Chatani, N., Shinonome, S., Ueyama, A., Kuwabara, K., & Fujio, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305984 · Cited by 5
Chen, S., Jin, L., Zeng, Z., & Chen, G. (2024) · Materials & Design · doi:10.1016/j.matdes.2024.113242 · Cited by 6
Zheng, X., Song, X., Zhang, B., Chen, X., Zhang, Y., Luo, Q., Li, Z., Deng, Z., Xu, R., Peng, L., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01500-2 · Cited by 4
Zhou, L., Li, Y., Wang, L., Chen, K., Zhou, S., Chen, Y., Sun, J., Tong, Y., & Fan, Y. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251348310 · Cited by 5
Ansardamavandi, A., Dumesny, C., Ma, Y., Dong, L., Ellis, S. L., Ang, C., Nikfarjam, M., & He, H. Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178357 · Cited by 5
Yan, Z., Yao, Z.-H., Yao, S.-N., Xia, Q.-X., Wang, H.-Y., Chu, J., Song, M., Zhao, S., & Liu, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s254007 · Cited by 5
Self-citationNormalizing the Tumor Microenvironment for Radiosensitization
Martin, J. D., & Jain, R. K. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_12 · Cited by 5
Witte, H. M., Gebauer, N., & Steinestel, K. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103592 · Cited by 5
Anti-angiogenic Therapy-Mediated Endothelial Damage: A Driver of Breast Cancer Recurrence?
Pisarsky, L., & Ghajar, C. M. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-97746-1_2 · Cited by 5
CD49a Targeting Enhances NK Cell Function and Antitumor Immunity
Zhang, Y., Li, Y., Zhang, Z. H., Zheng, X., Peng, H. C., Tian, Z., Sun, R., & Sun, H. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0124 · Cited by 5
Laheurte, C., Boullerot, L., Ndao, B., Malfroy, M., Queiroz, L., Guillaume, P., Loyon, R., Seffar, E., Gravelin, E., Renaudin, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102196 · Cited by 5
Zhang, Y., Yang, C., Guo, J., Yan, L., Li, Y., & Ye, Z. (2025) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x2550048x · Cited by 4
Venetoclax Synergizes With Regorafenib for Colorectal Cancer by Targeting BCL‐2
Zhu, L., Wang, W., Dong, Y., Han, X., Zhang, W., Zhang, Z., Guo, W., & Gu, Y. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.70017 · Cited by 4
Zhang, M., Liu, L., Zheng, H., Chen, M., & Li, J. (2025) · Immunologic Research · doi:10.1007/s12026-025-09621-w · Cited by 4
T cells in cardiovascular disease: solved and unsolved mysteries
Hou, Y., Gao, W., Zhou, B., & Lui, K. O. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2976-8 · Cited by 4
Wang, W.-D., Yang, C.-H., Mo, W., Li, S.-R., Yang, Q.-Q., Xie, J., Zhong, Y.-H., Zhang, J., Huang, C., Deng, W., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c19047 · Cited by 4
Self-citationBiopterin metabolism and nitric oxide recoupling in cancer
Clark, G. C., Lai, A., Agarwal, A., Liu, Z., & Wang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1321326 · Cited by 4
Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer
Lin, F., Chen, Y., Huang, B., Ruan, S., Lin, J., Chen, Z., Huang, C., & Zhao, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1391562 · Cited by 4
Wang, D., Qiu, C.-J., Chu, Y., Zhang, A., Huang, R., Pan, S.-J., & Tan, L. (2024) · Biomaterials Research · doi:10.34133/bmr.0117 · Cited by 4
Wei, X., Xing, X., Yao, W., Wang, C., Xiao, Y., & Du, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1473578 · Cited by 4
Zhao, J., Li, X., Sun, X., Xiao, R., Xue, J., Sui, K., & Liu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1533700 · Cited by 4
Zhang, W., Xiong, J., Li, Y., Nie, J., Zhao, W., Guo, Z., Liu, X., Zhang, Q., Chen, X., Li, Y., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251338046 · Cited by 4
Self-citationImmunotherapy and radiotherapy: An effective combination in cancer treatment
Li, X., Wang, C., Yang, H., Xue, W., Ding, Y.-Q., Wu, N., Pei, B., Ma, X., & Yang, W. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003609 · Cited by 5
Cui, B., Cao, X., Zou, W., Wan, Y., Wang, N., Wang, Y., Li, P., Hua, F., Liu, Y., Zhang, X., et al. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.06.007 · Cited by 4
Self-citationLet there be oxygen and T cells
Walker, P. R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci124305 · Cited by 4
Metadata
- Authors
- Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., Phung, T. L., Mani, S. A., Stossi, F., Sreekumar, A., Mancini, M. A., Decker, W. K., Zong, C., Lewis, M. T., & Zhang, X. H.-F.
- Affiliations
- Baylor College of Medicine (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Zhang, Xiaomei
- Zhang, Xiang H.-F.
- ORCID
- Venue
- Nature
- Published
- 2017-04
- Volume
- 544
- Issue
- 7649
- Pages
- 250-254
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5788037
- OpenAlex
- W2601414401
- Cited by
- 841
- References
- 36
- Citations by year
- 2026: 88 · 2025: 98 · 2024: 98 · 2023: 100 · 2022: 92 · 2021: 129 · 2020: 97 · 2019: 63 · 2018: 51 · 2017: 25
- FWCI
- 26.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (1s10od016167-01)
- National Cancer Institute (R00CA151293, R01CA220297, K99CA151293, R21CA185516, U01CA179674, R01CA183878, P30CA125123)
- National Institute of Allergy and Infectious Diseases (P30AI036211, R01AI127387)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK056338)
- National Center for Research Resources (S10RR024574)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- tumor immunosuppression, pericyte coverage, tumor hypoxia, CD4+ T cells, Th1 cells, interferon-gamma, immune checkpoint blockade, anti-angiogenic therapy, T cell infiltration, endothelial cells, tumor vasculature, patient-derived xenografts, cancer immunotherapy
- MeSH terms
- Animals, Capillary Permeability, Female, Humans, Interferon-gamma, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, Neovascularization, Pathologic, Prognosis, CD4-Positive T-Lymphocytes, Cell Hypoxia, Lymphocytes, Tumor-Infiltrating, Th1 Cells, Neovascularization, Physiologic, Adoptive Transfer, Pericytes, Xenograft Model Antitumor Assays, Endothelial Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
